Helsinn Group and Purdue Pharma (Canada) has announced that they have signed a distribution and licence agreement granting Purdue Pharma (Canada) exclusive rights to distribute, promote, market and sell ALOXI® (palonosetron hydrochloride) in Canada.
ALOXI® is an anti-emetic (5-HT3 receptor antagonist) authorized for sale by Health Canada in adults for the prevention of chemotherapy-induced nausea and vomiting (CINV)I.
ALOXI® is approved in over 70 countries worldwide, including the United States, European countries and Japan.
Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: “ALOXI® has helped to provide relief from CINV to patients across the world and, through this agreement with Purdue Pharma (Canada) we hope to extend its benefits to a greater number of patients in Canada. We are also pleased to be able to broaden our relationship with Purdue/Mundipharma Network, a trusted partner that we work with in many countries across 5 continents and look forward to working with them in Canada”.
Dr. Craig Landau, Purdue Pharma (Canada) CEO added: “Patients deserve access to medicines and treatments that help them manage their symptoms so they can participate fully in the things that matter most to them. Purdue Pharma (Canada) already offers medicines that benefit patients with cancer who also suffer from pain. Now, we can also help those who suffer from CINV. ALOXI® is a natural addition to our expanding portfolio.”